An interventional study of Liraglutide and Semaglutide in Metformin, Obesity, Abdominal and Diabetes Mellitus, Type 2, sponsored by RenJi Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-05-16.
Sponsored by RenJi Hospital · Not applicable, Interventional, and Treatment
How we know · 8 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Obesity, Abdominal with a site in China — 6 open to participants now, 7 under way, 1 of them phase 3. Obesity, Abdominal · China.
Among the 19 studies in Obesity, Abdominal with a site in China, this one is the 5th largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2023, is one of 12 with no phase, and was the 12th registered.
295 studies on the registry are indexed under Obesity, Abdominal; 45 are open to participants now.
Browse Obesity, Abdominal studies →6 of the 19 studies in Obesity, Abdominal with a site in China are open now. Recruiting first, the newest first:
Amway (China) R&D Center · Sites in China
Ages 30–65 · Healthy volunteers
Eli Lilly and Company · Sites in China, United States, Argentina and 9 more countries
Ages 18+
Guang'anmen Hospital of China Academy of Chinese Medical Sciences · Sites in China
Ages 18–64
Chinese University of Hong Kong · Sites in China
Ages 18–65
Zhejiang Provincial Tongde Hospital · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 26 Obesity, Abdominal studies recruiting now, 3 (12%) set no upper age limit and 21 (81%) stop at 75 or younger; 1 takes children under 18; 10 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 58 across 235 interventional studies indexed under Obesity, Abdominal.
Median enrollment 120 across the 17 interventional studies, 211 across the 2 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 19 have an industry lead sponsor. The 10 most frequent:
RenJi Hospital is the lead sponsor of 551 studies on the registry; 248 are open to participants now.
RenJi Hospital has 1 study filed under Obesity, Abdominal — fewer than ten, so there is no comparison to draw.
4 of the studies in Obesity, Abdominal with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05749874China National Center for Cardiovascular DiseasesEffects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus | 2026-12-31 |
| NCT07924956Amway (China) R&D CenterExplore the Weight Loss Effect of Amway "BODY TRIMMER" | 2027-02 |
| NCT06359418Guang'anmen Hospital of China Academy of Chinese Medical SciencesAcupuncture for Prediabetes With Combined Obesity | 2027-06-01 |
| NCT07759323Zhejiang Provincial Tongde HospitalPolygonatum Sibiricum Reduces Visceral Fat in Obese Adults | 2027-07-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Obesity, Abdominal with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to analyze the effects of GLP-1RA on blood glucose, body weight, glucose and lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes mellitus.
Specific research contents: To study the characteristics of glucose and lipid metabolism and fat distribution in overweight/obesity patients with type 2 diabetes mellitus; liraglutide/ semaglutide/ metformin will be applied to patients for one year, and the changes of lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes and the differences among the three groups will be analyzed before and after treatment. The metabolomic changes of overweight/obese patients with type 2 diabetes before and after medication and the differences among the three groups will be analyzed. Explore the correlation between visceral fat content, glucose and lipid metabolism, inflammatory factors and other biochemical indicators and metabolomics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Liraglutide is injected once a day.
Drug: Liraglutide
Semaglutide is injected once a week.
Drug: Semaglutide
Metformin is taken orally daily.
Drug: Metformin
Liraglutide is injected once a day.
Semaglutide is injected once a week.
Metformin is taken orally daily.
Blood glucose
Glucose metabolism index
Time frame: The twelfth week of treatment
Blood insulin
Glucose metabolism index
Time frame: The twelfth week of treatment
Total cholesterol
Lipid metabolism index
Time frame: The twelfth week of treatment
Triglyceride
Lipid metabolism index
Time frame: The twelfth week of treatment
Lipoprotein
Lipid metabolism index
Time frame: The twelfth week of treatment
Weight
Measure fasting weight
Time frame: The twelfth week of treatment
Abdominal fat distribution
Use Magnetic resonance imaging-proton density fat fraction to measure fat accumulation in the liver, pancreas and abdomen.
Time frame: The twelfth week of treatment
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Feb 2025, 24 months after the start.
Of 107 non-industry interventional studies with no phase under Obesity, Abdominal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 24 months is above that.
Counting every sponsor, half of 117 studies reached it within 16 months; a quarter within 7 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Liraglutide · Semaglutide · Metformin